Loading stock dataβ¦
$12.80+0.03 (+0.23%)
Dr.
Dr. Reddy's Laboratories Limited in the Healthcare sector is trading at $12.80 with a market capitalization of $10.4B. Wall Street consensus targets $13.81 (5 analysts), implying a +7.9% move over the next 12 months. The stock is currently 18% below its 52-week high of $15.67, remaining 2.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $80.70Bβ | $75.16Bβ | $87.27Bβ | $88.05Bβ | $85.45B |
| Gross Profit | $37.54Bβ | $43.03Bβ | $46.81Bβ | $48.14Bβ | $48.63B |
| Operating Income | $3.03Bβ | $829.00Mβ | $14.33Bβ | $17.87Bβ | $16.84B |
| Net Income | $4.43Bβ | $2.21Bβ | $12.10Bβ | $14.37Bβ | $14.18B |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Ac...